In Vivo Model Development for Staphylococcus Aureus Infection

Ace Therapeutics offers a comprehensive in vivo animal model development service for Staphylococcus aureus infection research. Leveraging a broad spectrum of validated animal models, we enable pharmaceutical, biotechnology, and academic partners to accelerate the discovery and evaluation of novel anti-staphylococcal therapies. Our expertise spans multiple species, infection modalities, and host backgrounds, ensuring tailored solutions to address the complex challenges of S. aureus pathogenesis and treatment.

Staphylococcus aureus is a leading cause of hospital- and community-acquired infections, including skin and soft tissue infections, pneumonia, endocarditis, and sepsis. The emergence of antibiotic-resistant strains, such as MRSA, underscores the urgent need for innovative therapeutics. Animal models are indispensable tools in S. aureus research, providing critical insights into host-pathogen interactions, disease progression, and therapeutic efficacy. At Ace Therapeutics, we employ a diverse array of species—including Caenorhabditis elegans (worms), Drosophila melanogaster (fruit flies), Galleria mellonella (wax moth larvae), Danio rerio (zebrafish), Cavia porcellus (guinea pigs), Mus musculus (mice), Rattus norvegicus (rats), Oryctolagus cuniculus (rabbits), and Sus scrofa (pigs)—across a variety of strains and immunological backgrounds. This diversity enables modeling of both localized and systemic infections, recapitulating key aspects of human disease and supporting translational research.

Immunocompetent and Immunocompromised Models

These models utilize animals with either normal (immunocompetent) or altered (immunocompromised, neutropenic, or immunosuppressed) immune systems to study S. aureus infection. Immunocompetent models employ standard laboratory strains (e.g., Balb/c, C57BL/6, Swiss, and Wistar), providing robust data on host-pathogen interactions and therapeutic efficacy under physiological conditions. Immunocompromised variants are generated via genetic manipulation (e.g., nude, knockout), chemical agents (e.g., cyclophosphamide, uranyl nitrate), or targeted depletion of immune cells (e.g., neutropenia). These models are invaluable for evaluating infection susceptibility, persistence, and drug efficacy in vulnerable patient populations, and for dissecting immune mechanisms underlying disease.

Genetically Modified and Mutant Models

Genetic models involve animals with targeted mutations or gene knockouts (e.g., Fpr2 knockout, glp-4 and sek-1 mutants in C. elegans) that impact immune function or susceptibility to infection. These models are developed using advanced genetic engineering or selective breeding techniques. The primary advantage is the ability to interrogate specific host factors and pathways involved in S. aureus infection and immunity. Applications include mechanistic studies of host defense, identification of novel drug targets, and validation of immune-modulatory therapies.

Device-Associated and Procedure-Induced Models

These models simulate clinical scenarios such as biofilm formation on implanted devices (e.g., stainless steel wire coil in Galleria mellonella, vascular grafts in rats), skin barrier disruption (shaved skin- or punch-induced models in mice), or mechanical interventions (mechanical ventilation-induced infection in pigs, jugular vein ligation in rabbits). Methodologies involve surgical or procedural induction followed by S. aureus inoculation. These models closely mimic human risk factors for infection, enabling the evaluation of anti-biofilm agents, wound therapeutics, and device coatings. They are particularly relevant for preclinical testing of interventions targeting hospital-acquired and device-related infections.

Chemically-Induced and Environmental Models

Chemically-induced models employ agents such as cyclophosphamide or uranyl nitrate to transiently suppress immune function or induce neutropenia prior to S. aureus challenge. Environmental models include air-induced or fasted conditions to modulate host susceptibility. The advantage of these approaches is the reproducible induction of defined host states, allowing for controlled studies of infection dynamics and drug efficacy under compromised conditions. These models are often used in early-stage efficacy screening and in studies of infection in immunosuppressed patient populations.

Alternative Host Models (Invertebrates and Lower Vertebrates)

Ace Therapeutics offers S. aureus infection models in alternative hosts such as C. elegans, D. melanogaster, G. mellonella, and D. rerio. These models utilize straightforward infection protocols with rapid readouts (e.g., survival, bacterial burden, immune activation). Advantages include cost-effectiveness, high throughput, and the ability to perform large-scale screens. They are ideal for preliminary efficacy, toxicity, and mechanistic studies, and serve as valuable complements to mammalian models.

Ace Therapeutics provides a full-service solution for S. aureus infection model development and therapeutic testing. Our offering encompasses model selection and customization, infection induction, dosing and administration of test agents, and comprehensive monitoring. Key efficacy endpoints include survival, bacterial load quantification (CFU counts in blood, tissues, or organs), lesion size and severity, histopathology, immune response profiling (cytokines, immune cell infiltration), and biofilm assessment. Our analytical capabilities span microbiology, molecular biology, immunology, and advanced imaging. Rigorous quality control is maintained through standardized protocols, experienced animal care, ethical oversight, and robust data validation to ensure reproducibility and scientific integrity.

Partnering with Ace Therapeutics provides access to a diverse portfolio of scientifically validated S. aureus infection models, expert study design, and end-to-end project support. Our integrated approach accelerates your anti-infective research, de-risks preclinical development, and delivers actionable data for regulatory submissions. Contact our team today to discuss your project needs and discover how our in vivo modeling expertise can drive your therapeutic innovation forward.